NANOBIOTIX : Nanobiotix to present preclinical data on nanoparticle radioenhancer NBTXR3 at the AACR Annual Meeting 2017
March 07 2017 - 2:40AM
NANOBIOTIX TO PRESENT PRECLINICAL DATA ON
NANOPARTICLE RADIOENHANCER NBTXR3 AT THE
AACR ANNUAL MEETING 2017
- Antitumor efficacy of NBTXR3 in different types of
tumors - in vivo preclinical data
- Antitumor efficacy of NBTXR3 when combined with
chemotherapy - in vitro and in vivo data
Paris, France and Cambridge, Massachusetts,
March 7, 2017 - NANOBIOTIX (Euronext: NANO - ISIN:
FR0011341205), a late clinical-stage nanomedicine company
pioneering new approaches to the local treatment of cancer, today
announced the presentation of NBTXR3 preclinical studies
demonstrating 1) the antitumor efficacy of NBTXR3 in five different
in vivo human cancer models and 2) the antitumor efficacy of NBTXR3
in combination with chemotherapy, in both in vitro and in vivo
studies. These data will be presented at the American Association
for Cancer Research (AACR) Annual Meeting 2017 in Washington, D.C
(April 1-5, 2017).
A key part of the non-clinical development
stands in building strategies to use NBTXR3 product across oncology
as a single agent and in combination with other cancer treatments
modalities. An increasing number of cancer models including
patient's tumor fragments have been evaluated in vitro and in vivo,
with NBTXR3 and radiotherapy, increasing evidence of
transferability of antitumor effects within very diverse
tumors.
"These NBTXR3 preclinical data highlight the
Nanobiotix' nanoparticles potential to treat different types of
cancers" said Laurent Levy, CEO of Nanobiotix. "These results
reinforce the rationale and level of scientific evidence to reach
our long-term goal development of NBTXR3 in most cancer patients
candidates to radiation treatment."
"Hafnium oxide nanoparticles (NBTXR3), a
novel radiation enhancer achieves marked antitumor efficacy across
five tumor types" Abstract number :17-A-2547
Nanobiotix will present data illustrating the
marked anti-tumor efficacy of NBTXR3 with radiotherapy, in in vivo
conditions. NBTXR3 showed superiority when compared to the sole use
of radiation in soft tissue sarcoma, prostate, head & neck,
colorectal and lung cancer models including patient's tumor
fragment of prostate adenocarcinoma. These studies also showed
NBTXR3 to have intratumor persistence of nanoparticles over time in
all evaluated cancer types. In addition, animals tolerated the
treatment very well.
"The radioenhancer NBTXR3 brings anticancer
efficacy to the cisplatin-based chemoradiation in
vitro and in vivo" Abstract number
:17-A-1065
Nanobiotix will also present data highlighting
the signs of NBTXR3's antitumor efficacy when combined with
cisplatin-based chemoradiation both in vitro and in vivo. Cisplatin
is a cytotoxic agent that inhibits DNA repair of sub-lethal damage
from irradiation. Chemoradiation of this type is currently the
primary treatment for patients with high-risk head and neck
cancers, cervix and non-small cell lung cancers. Nanobiotix' in
vivo and in vitro results revealed that adding NBTXR3 significantly
improves the anticancer effect of the chemoradiation. This research
was performed in collaboration with Professor Bo Lu, from the
Cancer Center of Thomas Jefferson University in Philadelphia,
PA.
***
About American Association for Cancer Research
(AACR) www.aacr.org
The AACR Annual Meeting is one of the main
international oncology event highlighting the best cancer science
and medicine from institutions all over the world. The American
Association for Cancer Research (AACR) Annual Meeting 2017 will
take place in Washington, D.C (April 1-5, 2017).
About NANOBIOTIX: www.nanobiotix.com
Nanobiotix (Euronext: NANO / ISIN: FR0011341205)
is a late clinical-stage nanomedicine company pioneering novel
approaches for the local treatment of cancer. The Company's
first-in-class, proprietary technology, NanoXray, enhances
radiotherapy energy with a view to provide a new, more efficient
treatment for cancer patients.
NanoXray products are compatible with current
radiotherapy treatments and are meant to treat potentially a wide
variety of solid tumors including soft tissue sarcoma, head and
neck cancers, liver cancers, prostate cancer, breast cancer,
glioblastoma, etc., via multiple routes of administration.
NBTXR3 is being evaluated in: soft tissue
sarcoma (STS), head and neck cancers, prostate cancer, and liver
cancers (primary and metastases). Additionally, head and neck
cancer and rectal cancer trials led by Nanobiotix's Taiwanese
partner, PharmaEngine, are underway in the Asia Pacific region. The
Company has filed in August 2016 for market approval (CE Marking)
in Europe for its lead product NBTXR3.
The Company started in 2016 a new preclinical
research program in Immuno-oncology with its lead product NBTXR3,
which could have the potential to bring a new dimension to cancer
immunotherapies.
Nanobiotix is listed on the regulated market of
Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO,
Bloomberg: NANO: FP). The Company Headquarter is based in Paris,
France. Affiliate in Cambridge, United States.
Contact
Nanobiotix |
Sarah GaubertDirector, Communication & Public
Affairs+33 (0)1 40 26 07 55sarah.gaubert@nanobiotix.com
/contact@nanobiotix.com |
Noël Kurdi Director, Investor
Relations +1 (646) 241-4400 noel.kurdi@nanobiotix.com /
investors@nanobiotix.com |
Media relations |
France -
Springbok ConsultantsMarina Rosoff+33 (0)6 71 58 00
34marina@springbok.fr |
|
United States -
RooneyPartners Marion Janic +1 (212)
223-4017mjanic@rooneyco.com |
|
DisclaimerThis press release contains certain
forward-looking statements concerning Nanobiotix and its business,
including its prospects. Such forward-looking statements are based
on assumptions that Nanobiotix considers to be reasonable. However,
forward-looking statements are not guarantees of future performance
as they relate to future events and are dependent on circumstances
that may or may not materialize in the future, and on a variety of
risks and uncertainties, including those set forth in the update of
the reference document filed by Nanobiotix with the French
Financial Markets Authority (Autorité des Marchés Financiers) under
number D.16-0732-A01 on December 27, 2016 (a copy of which is
available on www.nanobiotix.com) and on the development of economic
conditions, financial markets and the markets in which Nanobiotix
operates. The forward-looking statements contained in this press
release are also subject to risks not yet known to Nanobiotix or
not currently considered material by Nanobiotix. The occurrence of
all or part of such risks could cause actual results, financial
conditions, performance or achievements of Nanobiotix to be
materially different from such forward-looking statements.
Nanobiotix disclaims any responsibility for updating any such
forward-looking statements.
This press release and the information that it
contains do not constitute an offer to sell or subscribe for, or a
solicitation of an offer to purchase or subscribe for, Nanobiotix
shares or other securities in any country. At the present time,
NBTXR3 does not bear a CE mark and, consequently, may not be placed
on the market or used until such time as a CE mark is obtained.
Nanobiotix (EU:NANO)
Historical Stock Chart
From May 2024 to Jun 2024
Nanobiotix (EU:NANO)
Historical Stock Chart
From Jun 2023 to Jun 2024